- Home
- AMPY vs CRDF Comparison
AMPY vs CRDF Comparison
Compare AMPY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- CRDF
- Stock Information
- Founded
- AMPY 2011
- CRDF 1999
- Country
- AMPY United States
- CRDF United States
- Employees
- AMPY N/A
- CRDF N/A
- Industry
- AMPY Oil & Gas Production
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMPY Energy
- CRDF Health Care
- Exchange
- AMPY Nasdaq
- CRDF Nasdaq
- Market Cap
- AMPY 208.5M
- CRDF 240.2M
- IPO Year
- AMPY 2011
- CRDF N/A
- Fundamental
- Price
- AMPY $5.41
- CRDF $4.24
- Analyst Decision
- AMPY Strong Buy
- CRDF Strong Buy
- Analyst Count
- AMPY 3
- CRDF 3
- Target Price
- AMPY $10.00
- CRDF $10.33
- AVG Volume (30 Days)
- AMPY 396.3K
- CRDF 1.0M
- Earning Date
- AMPY 03-05-2025
- CRDF 02-27-2025
- Dividend Yield
- AMPY N/A
- CRDF N/A
- EPS Growth
- AMPY N/A
- CRDF N/A
- EPS
- AMPY 1.55
- CRDF N/A
- Revenue
- AMPY $304,645,000.00
- CRDF $688,000.00
- Revenue This Year
- AMPY $8.52
- CRDF $25.03
- Revenue Next Year
- AMPY $17.67
- CRDF N/A
- P/E Ratio
- AMPY $3.48
- CRDF N/A
- Revenue Growth
- AMPY 17.42
- CRDF 49.57
- 52 Week Low
- AMPY $3.56
- CRDF $1.47
- 52 Week High
- AMPY $8.15
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- AMPY 28.26
- CRDF 60.32
- Support Level
- AMPY $5.21
- CRDF $3.78
- Resistance Level
- AMPY $6.62
- CRDF $4.23
- Average True Range (ATR)
- AMPY 0.22
- CRDF 0.22
- MACD
- AMPY -0.05
- CRDF 0.06
- Stochastic Oscillator
- AMPY 0.37
- CRDF 88.93
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana, and Eagle Ford.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").